FIELD: biochemistry.
SUBSTANCE: this invention relates to biochemistry, in particular to new polypeptides binding a human CD3 antigen and to molecules of bispecific antibodies capable of activating immune effector cells, as well as to their production and use in diagnostics or treatment of different diseases.
EFFECT: invention is aimed at reduction in a toxic effect of therapy using anti-CD3 antibodies with preservation of antitumor efficiency due to reduction in release of cytokines and reduction in off-target activation of T-cells.
58 cl, 10 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ANTIBODY AND USE THEREOF | 2021 |
|
RU2839153C2 |
| ANTIBODIES BINDING CD3 | 2017 |
|
RU2779489C2 |
| ANTIBODIES BINDING TO GPRC5D | 2020 |
|
RU2841523C2 |
| TUMOR-TARGETING AGONIST CD28 ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2837821C1 |
| IMPROVED ANTI-FLT3 ANTIGEN-BINDING PROTEINS | 2019 |
|
RU2830982C2 |
| ANTIBODIES BINDING TO GPRC5D | 2019 |
|
RU2797268C2 |
| PROTEASE-ACTIVATED T-CELL BINDING BISPECIFIC MOLECULES | 2017 |
|
RU2830288C2 |
| ANTIBODY TO CD3 AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2802272C2 |
| BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD3 | 2020 |
|
RU2827106C1 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2022 |
|
RU2824285C2 |
